Anzeige
Mehr »
Login
Dienstag, 24.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
726 Leser
Artikel bewerten:
(2)

Nasdaq, Inc.: Annual Changes to the Nasdaq Biotechnology Index

Finanznachrichten News

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20, 2021.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market (Nasdaq) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The following 129 securities will be added to the Index:

ExchangeTickerCompany
NasdaqBTXBrooklyn ImmunoTherapeutics, Inc.
NasdaqLXRXLexicon Pharmaceuticals, Inc.
NasdaqCRISCuris, Inc.
NasdaqHBIOHarvard Bioscience, Inc.
NasdaqEYPTEyePoint Pharmaceuticals, Inc.
NasdaqMTEMMolecular Templates, Inc.
NasdaqVIRXViracta Therapeutics, Inc.
NasdaqAVXLAnavex Life Sciences Corp.
NasdaqINFIInfinity Pharmaceuticals, Inc.
NasdaqHROWHarrow Health, Inc.
NasdaqTNXPTonix Pharmaceuticals Holding Corp.
NasdaqCMRXChimerix, Inc.
NasdaqADMAADMA Biologics Inc
NasdaqSESNSesen Bio, Inc.
NasdaqCLSDClearside Biomedical, Inc.
NasdaqPRQRProQR Therapeutics N.V.
NasdaqALPNAlpine Immune Sciences, Inc.
NasdaqACRSAclaris Therapeutics, Inc.
NasdaqNVCRNovoCure Limited
NasdaqMRUSMerus N.V.
NasdaqOCXOncocyte Corporation
NasdaqCRVSCorvus Pharmaceuticals, Inc.
NasdaqLPTXLeap Therapeutics, Inc.
NasdaqOBSVObsEva SA
NasdaqMBIOMustang Bio, Inc.
NasdaqOPTNOptiNose, Inc.
NasdaqSLDBSolid Biosciences Inc.
NasdaqNRXPNRX Pharmaceuticals, Inc.
NasdaqEOLSEvolus, Inc.
NasdaqCOGTCogent Biosciences, Inc.
NasdaqMREOMereo BioPharma Group plc
NasdaqAQSTAquestive Therapeutics, Inc.
NasdaqEVLOEvelo Biosciences, Inc.
NasdaqVRCAVerrica Pharmaceuticals Inc.
NasdaqGRTSGritstone bio, Inc.
NasdaqINBXInhibrx, Inc.
NasdaqBCYCBicycle Therapeutics plc
NasdaqCDAKCodiak BioSciences, Inc.
NasdaqMIRMMirum Pharmaceuticals, Inc.
NasdaqIMPLImpel NeuroPharma, Inc.
NasdaqMORFMorphic Holding, Inc.
NasdaqOYSTOyster Point Pharma, Inc.
NasdaqETNB89bio, Inc.
NasdaqPHATPhathom Pharmaceuticals, Inc.
NasdaqFDMT4D Molecular Therapeutics, Inc.
NasdaqCVACCureVac N.V.
NasdaqHRMYHarmony Biosciences Holdings, Inc.
NasdaqVTRSViatris Inc.
NasdaqQSIQuantum-Si Incorporated
NasdaqPMVPPMV Pharmaceuticals, Inc.
NasdaqKYMRKymera Therapeutics, Inc.
NasdaqNAUTNautilus Biotechnology, Inc.
NasdaqDYNDyne Therapeutics, Inc.
NasdaqCCCCC4 Therapeutics, Inc.
NasdaqHUMAHumacyte, Inc.
NasdaqATHAAthira Pharma, Inc.
NasdaqLABPLandos Biopharma, Inc.
NasdaqTSHATaysha Gene Therapies, Inc.
NasdaqONCROncorus, Inc.
NasdaqPRAXPraxis Precision Medicines, Inc.
NasdaqCMPSCOMPASS Pathways Plc
NasdaqPRLDPrelude Therapeutics Incorporated
NasdaqBOLTBolt Biotherapeutics, Inc.
NasdaqABCMAbcam plc
NasdaqSTTKShattuck Labs, Inc.
NasdaqKRONKronos Bio, Inc.
NasdaqALGSAligos Therapeutics, Inc.
NasdaqAVIRAtea Pharmaceuticals, Inc.
NasdaqOLMAOlema Pharmaceuticals, Inc.
NasdaqSBTXSilverback Therapeutics, Inc.
NasdaqMRVIMaravai LifeSciences Holdings, Inc.
NasdaqBCABBioAtla, Inc.
NasdaqGRCLGracell Biotechnologies Inc.
NasdaqKNTEKinnate Biopharma Inc.
NasdaqSEERSeer, Inc.
NasdaqME23andMe Holding Co.
NasdaqKMPHKemPharm, Inc.
NasdaqBVSBioventus Inc.
NasdaqSNSESensei Biotherapeutics, Inc.
NasdaqSABSSAB Biotherapeutics, Inc.
NasdaqVORVor Biopharma Inc.
NasdaqABCLAbCellera Biologics Inc.
NasdaqCGEMCullinan Oncology, Inc.
NasdaqDBTXDecibel Therapeutics, Inc.
NasdaqCNTBConnect Biopharma Holdings Limited
NasdaqSANASana Biotechnology, Inc.
NasdaqACHLAchilles Therapeutics plc
NasdaqIKNAIkena Oncology, Inc.
NasdaqTERNTerns Pharmaceuticals, Inc.
NasdaqEWTXEdgewise Therapeutics, Inc.
NasdaqRXRXRecursion Pharmaceuticals, Inc.
NasdaqRXDXPrometheus Biosciences, Inc.
NasdaqTILInstil Bio, Inc.
NasdaqDSGNDesign Therapeutics, Inc.
NasdaqBMEABiomea Fusion, Inc.
NasdaqRAINRain Therapeutics Inc.
NasdaqATAIATAI Life Sciences N.V.
NasdaqCADLCandel Therapeutics, Inc.
NasdaqHOWLWerewolf Therapeutics, Inc.
NasdaqTALSTalaris Therapeutics, Inc.
NasdaqCYTCyteir Therapeutics, Inc.
NasdaqOMICSingular Genomics Systems, Inc.
NasdaqDNAYCodex DNA, Inc.
NasdaqCNTACentessa Pharmaceuticals plc
NasdaqIMGOImago BioSciences, Inc.
NasdaqIPSCCentury Therapeutics, Inc.
NasdaqSERASera Prognostics, Inc.
NasdaqRANIRani Therapeutics Holdings, Inc.
NasdaqVERVVerve Therapeutics, Inc.
NasdaqDAWNDay One Biopharmaceuticals, Inc.
NasdaqJANXJanux Therapeutics, Inc.
NasdaqTKNOAlpha Teknova, Inc.
NasdaqGLUEMonte Rosa Therapeutics, Inc.
NasdaqRPIDRapid Micro Biosystems, Inc.
NasdaqAVTEAerovate Therapeutics, Inc.
NasdaqERASErasca, Inc.
NasdaqTNYATenaya Therapeutics, Inc.
NasdaqICVXIcosavax, Inc.
NasdaqIMRXImmuneering Corporation
NasdaqRLYBRallybio Corporation
NasdaqGRPHGraphite Bio, Inc.
NasdaqABOSAcumen Pharmaceuticals, Inc.
NasdaqLYELLyell Immunopharma, Inc.
NasdaqABSIAbsci Corporation
NasdaqNUVLNuvalent, Inc.
NasdaqOMGAOmega Therapeutics, Inc.
NasdaqCRBUCaribou Biosciences, Inc.
NasdaqMXCTMaxCyte, Inc.
NasdaqBLUBELLUS Health Inc.

As a result of the reconstitution, the following 21 securities will be removed from the Index:

ExchangeTickerCompany
NasdaqMNOVMediciNova, Inc.
NasdaqASMBAssembly Biosciences, Inc.
NasdaqCNCEConcert Pharmaceuticals, Inc.
NasdaqARDXArdelyx, Inc.
NasdaqCALACalithera Biosciences, Inc.
NasdaqXBITXBiotech Inc.
NasdaqKALAKala Pharmaceuticals, Inc.
NasdaqVYGRVoyager Therapeutics, Inc.
NasdaqODTOdonate Therapeutics, Inc.
NasdaqVYNEVYNE Therapeutics Inc.
NasdaqUBXUnity Biotechnology, Inc.
NasdaqOSMTOsmotica Pharmaceuticals plc
NasdaqORTXOrchard Therapeutics plc
NasdaqKLDOKaleido Biosciences, Inc.
NasdaqBCELAtreca, Inc.
NasdaqAPREAprea Therapeutics, Inc.
NasdaqFUSNFusion Pharmaceuticals Inc.
NasdaqINZYInozyme Pharma, Inc.
NasdaqTSVTV2seventy bio, Inc.
NasdaqANIPANI Pharmaceuticals, Inc.
NasdaqDRNADicerna Pharmaceuticals, Inc.

About Nasdaq
Nasdaq.

Media Contact
Emily Pan
emily.pan@nasdaq.com
+1 (646) 637-3964

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

- NDAQG -


© 2021 GlobeNewswire (Europe)
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.